Jonsson Comprehensive Cancer Center
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.cancer.ucla.edu
Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance
Not Applicable
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Procedure: Focal Laser Ablation
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT06047509
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
Not Applicable
Recruiting
- Conditions
- Lung CarcinomaBreast Carcinoma
- Interventions
- Behavioral: Health EducationOther: Health Promotion and EducationBehavioral: Patient NavigationOther: Survey Administration
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 800
- Registration Number
- NCT05978128
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Withdrawn
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyOther: Fludeoxyglucose F-18Other: ImmunotherapyProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT05950113
- Locations
- πΊπΈ
Melanie Ayala Ceja, Los Angeles, California, United States
Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer
Early Phase 1
Terminated
- Conditions
- Resectable Pancreatic Carcinoma
- Interventions
- Biological: Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)Biological: Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)Procedure: Computed TomographyProcedure: X-Ray ImagingProcedure: Biospecimen CollectionOther: Survey AdministrationProcedure: Pancreatectomy
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT05841706
- Locations
- πΊπΈ
University of California at Los Angeles, Los Angeles, California, United States
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Phase 2
Recruiting
- Conditions
- Renal Pelvis and Ureter Urothelial Carcinoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionDrug: Enfortumab VedotinProcedure: MR UrographyProcedure: Nephroureterectomy
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05775471
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: Tagraxofusp-erzs
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT05720988
- Locations
- πΊπΈ
Habtemariam,Bruck, Los Angeles, California, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Phase 1
Recruiting
- Conditions
- Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Core Biopsy
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT05688215
- Locations
- πΊπΈ
Yonemoto,Lisa, Los Angeles, California, United States
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
Phase 2
Recruiting
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionDrug: Placebo AdministrationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT05595499
- Locations
- πΊπΈ
UCLA Health Cancer Care in Alhambra, Alhambra, California, United States
πΊπΈUCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills, California, United States
πΊπΈUCLA Health Burbank Primary & Specialty Care, Burbank, California, United States
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Phase 1
Recruiting
- Conditions
- Lung Adenocarcinoma
- Interventions
- Procedure: Computed TomographyOther: Laboratory Biomarker AnalysisProcedure: Positron Emission Tomography
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05558904
- Locations
- πΊπΈ
Yesenia Calzada, Los Angeles, California, United States
Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)
Not Applicable
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Other: Mobile Application
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT05523700
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States